TauroLock-HEP500 in Dialysis protects from infection and inflammation Ezzat

in Dialysis TauroLock™-HEP500 in dialysis ensures superior dialysis quality and protects from infection and inflammation Ezzat H., Elsharkawy M., Rezk K., Mohsen R., Mansour A., Emara A., 2021: Randomised study with temporary hemodialysis catheters, four weeks use of TauroLock™-HEP500 (30 patients) vs. heparin 5000 IU/ml (30 patients): Significantly better outcome with TauroLock™-HEP500 regarding inflammatory profile, CRBSI-rate and dialysis quality.

1. Dialysis adequacy and blood flow rate (BFR): Significantly better outcome for urea reduction rate (URR, p=0.007) and blood flow rate (BFR).

2. Catheter related bloodstream infections (CRBSI): 9 incidences in heparin-group vs. 1 in TauroLock™HEP500 group.

BFR (mean, mL/min), p=0.001* 300

35

CRBSI (% of patients), p=0.006*

30

*

25

290

20

280

15 270

*

10

260

5

Start

250

End

0

Heparin

Heparin

3. Inflammatory markers: TauroLock™-HEP500 prevents rise in white blood cell count (WBC) and maintains the level of high sensitivity C-reactive protein (hsCRP) and of Interleukin-6 (IL-6).

WBC (1000), p=0.045*

hsCRP (mg/mL), p=0.001*

300 9.5

*

280 270 260

290

10.5

290

Start

End

Heparin

8.5

*

7.5 6.5 5.5

IL-6 (pg/mL), p=0.018*

Start

End

Heparin

280

*

270 260

Start

End

Heparin

in Dialysis The results of this study confirm the outcome of the prospective study by Fontseré N., Soriano A., Mestres G., Bermudez P., Zarco F., Lozano V., Rodas L., Broseta J., Arias M., Maduell F., 2014: • a significantly reduced rate of CRBSI (Fontseré: 0.04 vs. 1.08 per 1000 CVC days, p=0.023) • an improved inflammatory profile • regarding need for thrombolytic treatment, Fontseré et al. declare lower costs (252 vs. 461 €).

helps to prevent catheter-related bloodstream infections and develop a superior dialysis quality in temporary as well as in long-term catheters.

It also prevents the chronic activation of the immune system compared to heparin, and may thus help to reduce the elevated mortality and morbidity of hemodialysis patients.

References: - Ezzat H., Elsharkawy M., Rezk K., Mohsen R., Mansour A., Emara A., 2021.

Effect of taurolidine citrate and unfractionated heparin on inflammatory state and dialysis adequacy in hemodialysis patients.

JVA 2021. https://doi.org/10.1177/11297298211023295 - Fontseré N., Soriano A., Mestres G., Bermudez P., Zarco F., Lozano V., Rodas L., Broseta J., Arias M., Maduell F., 2014.

Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.

Antimicrob Agents Chemother 2014; 58(7): 4180–4184.

89202GB/42/21